Внутрішньоміхурова БЦЖ-терапія — live attenuated Mycobacterium bovis immunotherapy for non-muscle-invasive bladder cancer after TURBT
Transurethral resection of bladder tumor (TURBT) is both diagnostic and therapeutic — it removes visible papillary tumors and provides tissue for staging and grading. Roughly 75% of newly diagnosed bladder cancers are non-muscle-invasive (NMIBC: Ta, T1, or carcinoma in situ/CIS), confined to the mucosa or lamina propria. Risk stratification after TURBT determines whether a patient needs no further therapy, a single chemotherapy instillation, or a full course of intravesical BCG immunotherapy.
TURBT resects the tumor down to and including detrusor muscle (when possible) so the pathologist can determine depth of invasion:
• Ta — non-invasive papillary carcinoma confined to the urothelium (mucosa only); the most common presentation, often low-grade • T1 — tumor invades the lamina propria (subepithelial connective tissue) but not detrusor muscle; carries substantially higher progression risk than Ta • Tis (CIS) — carcinoma in situ: a flat, high-grade lesion that can be easily missed on cystoscopy (velvety red patches) yet is biologically aggressive and a strong predictor of progression if untreated • T2+ — invasion into detrusor muscle defines muscle-invasive bladder cancer (MIBC), managed with radical cystectomy or trimodal therapy, not intravesical therapy
Repeat resection ("re-TURBT") within 2–6 weeks is recommended for high-grade T1 tumors or when detrusor muscle was absent in the initial specimen, because residual disease is found in 20–70% of these cases.
Detrusor muscle must be present in the TURBT specimen to reliably exclude muscle invasion — its absence is one of the strongest predictors of understaging and early recurrence.
Guidelines (EAU, AUA/SUO) stratify NMIBC into risk groups combining stage, grade, tumor size, multiplicity, and CIS status:
• Low risk: primary, solitary, Ta, low-grade, <3 cm, no CIS — recurrence managed with a single immediate post-TURBT chemotherapy instillation (mitomycin C), no BCG needed • Intermediate risk: recurrent Ta low-grade, or multifocal, or >3 cm, without high-grade features — adjuvant intravesical chemotherapy or a shorter BCG course • High risk: any T1, any high-grade/Grade 3, any CIS, or multiple/large/recurrent high-grade Ta tumors — full induction + maintenance BCG (or radical cystectomy for very high-risk subsets) • Very high risk: T1 high-grade with CIS, lymphovascular invasion, variant histology, or BCG-unresponsive disease — early cystectomy strongly considered
Risk group assignment is the single most important decision point: it dictates whether BCG immunotherapy — the focus of this simulation — is indicated at all.
Intravesical BCG is deliberately timed 2–4 weeks after TURBT (never immediately, to avoid systemic BCG absorption through a raw resection bed and risk of BCG sepsis):
• TURBT exposes the basement membrane and lamina propria fibronectin — the very substrate BCG bacilli need to attach to urothelial and residual tumor cells • The controlled surgical wound response primes local immune surveillance, synergizing with the BCG-induced inflammatory cascade • Residual microscopic disease (positive margins, satellite CIS, cells shed into urine) is the actual target of BCG — it is an adjuvant immunotherapy, not a debulking agent
BCG is contraindicated with active gross hematuria, traumatic catheterization, active urinary tract infection, or immunosuppression, all of which raise the risk of bacillemia.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Low risk | Primary, solitary Ta LG, <3cm, no CIS | Single immediate post-TURBT chemo instillation (mitomycin C/gemcitabine) | No BCG required; cystoscopic surveillance only |
| Intermediate risk | Recurrent/multifocal Ta LG, 3cm+ | Adjuvant intravesical chemotherapy course OR 1-year BCG (induction + 1 maintenance) | Reduces recurrence; chemo often preferred to spare BCG supply |
| High risk | Any T1, high-grade Ta, or CIS | 6-week induction BCG + SWOG maintenance up to 3 years | ~30–40% recurrence reduction, delays/prevents progression |
| Very high / BCG-unresponsive | T1 HG+CIS, LVI, variant histology, BCG failure | Early radical cystectomy or clinical trial / novel intravesical agent | Avoids progression to incurable muscle-invasive disease |
Bacillus Calmette-Guérin is a live, attenuated strain of Mycobacterium bovis originally developed as a tuberculosis vaccine in 1921. Morales, Eidinger, and Bruce first demonstrated its antitumor effect in the bladder in 1976. Today it remains the single most effective intravesical agent for high-risk NMIBC — but its mechanism depends on precise physical delivery and molecular attachment to the urothelium.
BCG substrains (TICE, Connaught, RIVM, Tokyo-172, Moreau) descend from the original Calmette-Guérin isolate, attenuated over 231 in vitro passages (1908–1921) from virulent M. bovis. Genomic deletions (notably RD1, encoding the ESAT-6/CFP-10 virulence factors) render BCG safe for intravesical use while preserving its potent immunostimulatory cell-wall components — mycolic acids, arabinogalactan, peptidoglycan, and lipoarabinomannan — that are recognized by innate pattern-recognition receptors.
Before instillation, the bladder is fully drained by catheter. The lyophilized BCG vial is reconstituted and diluted in ~50 mL sterile saline, then instilled through the same catheter under gravity, avoiding trauma to the urothelium.
After instillation, the patient retains the BCG suspension for approximately 2 hours, repositioning (supine, prone, left/right lateral) every 15–30 minutes to maximize contact of the bacilli with the entire urothelial surface.
Attachment mechanism: • BCG fibronectin attachment protein (FAP, also called antigen 85 complex) on the mycobacterial cell wall binds fibronectin — an extracellular matrix glycoprotein exposed on damaged/resected urothelium and in the basement membrane • Integrin α5β1 on urothelial and tumor cells cooperates with fibronectin to mediate BCG adhesion • Attached bacilli are then internalized by both normal urothelial cells and residual tumor cells via macropinocytosis, entering endosomal/phagosomal compartments • Intracellular BCG persists for days, continuously presenting mycobacterial antigens and pathogen-associated molecular patterns (PAMPs) to the immune system — this sustained local stimulus is essential for the durable therapeutic effect
Without adequate fibronectin exposure (e.g., an intact, non-resected urothelium) BCG attachment and antitumor efficacy are markedly reduced — reinforcing why BCG is given only after TURBT.
Trauma from difficult catheterization or instilling BCG too soon after TURBT (or in the presence of gross hematuria) can allow live mycobacteria to enter the bloodstream — the principal mechanism behind rare but serious systemic BCGosis.
Each instillation uses one full-strength vial (dose varies slightly by manufacturer/strain, typically 1–8×10⁸ CFU); dose reduction (e.g., one-third dose) is sometimes used in maintenance or after significant local toxicity, though full-dose induction is standard when tolerated.
After the 2-hour dwell, the patient voids while seated (to reduce splash/aerosolization) and is instructed on decontamination of urine with undiluted bleach for the first several hours — a standard biosafety precaution given the shed live bacilli.
Within hours of BCG internalization, the bladder wall transforms from an immunologically quiescent organ into a site of intense innate immune activity. Urothelial cells and resident macrophages recognize mycobacterial PAMPs through Toll-like receptors, triggering a cytokine cascade that recruits massive numbers of neutrophils and monocytes into the urine and bladder wall — the cellular basis of BCG's antitumor effect.
Urothelial cells are not passive bystanders — they act as the first responders of the bladder immune system:
• TLR2 and TLR4 on urothelial cells and resident macrophages bind mycobacterial cell-wall lipoproteins and lipoarabinomannan (LAM) • NOD2 recognizes muramyl dipeptide from mycobacterial peptidoglycan intracellularly • Engagement triggers NF-κB signaling, driving transcription of a broad panel of pro-inflammatory chemokines and cytokines • Urothelial cells themselves secrete IL-6, IL-8 (CXCL8), and GM-CSF directly into the urine within the first 24–48 hours of instillation
This "danger signal" cascade converts the bladder lumen and wall into a highly chemotactic environment, actively drawing circulating leukocytes out of the bladder microvasculature.
Sequential waves of cytokines characterize a successful BCG response — this "cytokine signature" is measurable in urine and correlates with clinical outcome:
• IL-1 and TNF-α: early pro-inflammatory amplifiers, further activating endothelium (upregulating ICAM-1/VCAM-1 for leukocyte adhesion) • IL-6 and IL-8: peak within days, drive neutrophil chemotaxis and acute-phase response (explaining the fevers/flu-like symptoms many patients experience) • IL-12 (from activated macrophages/dendritic cells): the pivotal cytokine polarizing naive T cells toward a Th1 phenotype and activating NK cells • IL-2 and IFN-γ: hallmark Th1 cytokines; IFN-γ further activates macrophages in a feed-forward loop (classical macrophage activation) and upregulates MHC class I/II on tumor and antigen-presenting cells, enhancing tumor antigen presentation • TNF-α and IFN-γ synergize to induce direct antiproliferative and pro-apoptotic effects on bladder tumor cells
Patients whose urine shows a robust Th1 cytokine pattern (high IL-2, IFN-γ, IL-12) after induction have significantly better recurrence-free survival than those with a blunted or Th2-skewed response.
A dominant Th1 response (IL-2, IFN-γ, IL-12, IL-18) predicts favorable outcomes, while a Th2-skewed pattern (IL-10, IL-4) is associated with BCG failure — this is one of the clearest examples of cytokine polarization determining immunotherapy success in oncology.
By 24–72 hours post-instillation, voided urine contains enormous numbers of infiltrating leukocytes — this is directly visible as sterile pyuria:
• Neutrophils: the dominant early responder, recruited by IL-8/CXCL8 gradients; they phagocytose BCG and tumor debris and are a major early source of additional cytokines and reactive oxygen species • Monocytes/macrophages: differentiate locally, phagocytose BCG-coated and apoptotic tumor cells, and act as professional antigen-presenting cells bridging innate and adaptive immunity • Granulomas: repeated instillations over the 6-week induction course lead to formation of small BCG-induced granulomas in the lamina propria — a histological hallmark of an effective local immune response, analogous to the pulmonary granulomas of natural mycobacterial infection
This innate infiltrate is necessary but not sufficient for tumor clearance — it sets the stage for the adaptive, antigen-specific killing detailed in the next stage.
The innate inflammatory storm of the first days culminates in a targeted adaptive immune attack. Dendritic cells and macrophages that have processed BCG and tumor antigens migrate to draining lymph nodes and prime tumor-reactive T cells, while NK cells and cytotoxic T lymphocytes converge on the bladder wall to eliminate residual and recurrent tumor cells directly — with lasting immunological memory reducing future recurrence.
Dendritic cells that have phagocytosed BCG and apoptotic/necrotic tumor cell debris process and present both mycobacterial antigens and tumor-associated antigens (cross-presentation) on MHC class I and II:
• Migration to regional (iliac/pelvic) lymph nodes primes naive CD4+ and CD8+ T cells • IL-12 from activated macrophages/DCs drives differentiation of CD4+ T cells into Th1 helper cells, which in turn license CD8+ cytotoxic T lymphocyte (CTL) expansion via IL-2 and CD40L signaling • Expanded, activated T cells recirculate and infiltrate the bladder wall, guided by chemokine gradients (CXCR3 ligands induced by local IFN-γ)
The result is a bladder wall densely infiltrated by CD4+, CD8+, and memory T-cell populations by the later weeks of induction — visible histologically as a mixed inflammatory infiltrate surrounding residual tumor foci.
Multiple cytotoxic pathways converge on residual bladder tumor cells:
• Perforin/granzyme pathway: CTLs and NK cells release perforin, which polymerizes to form pores in the tumor cell membrane, allowing granzyme B entry — granzyme B cleaves caspases and initiates rapid apoptosis • Death-receptor pathway: TNF-α, FasL, and TRAIL expressed on activated immune cells engage death receptors (Fas/CD95, DR4/DR5) on tumor cells, triggering the extrinsic apoptotic cascade • NK and BCG-activated killer (BAK) cells: BCG stimulation generates a population of NK-like effector cells capable of non-MHC-restricted, broadly cytotoxic killing — important because bladder tumor cells often downregulate MHC class I to evade classical CTLs, but this simultaneously makes them more susceptible to NK "missing-self" recognition • Nitric oxide and reactive oxygen species from activated macrophages contribute additional direct cytotoxicity and anti-angiogenic effects within the tumor microenvironment
The cumulative effect over the 6-week induction course is progressive elimination of microscopic residual tumor and pre-malignant urothelial clones that TURBT alone leaves behind.
Because bladder tumor cells frequently downregulate MHC class I to escape cytotoxic T cells, the NK-cell and BAK-cell arm of the BCG response is disproportionately important — it exploits the very immune-evasion strategy the tumor uses against T cells.
A distinctive feature of BCG is its ability to induce "trained immunity" — long-lived functional reprogramming of innate immune cells (monocytes/macrophages, NK cells) through epigenetic changes (histone modification at cytokine gene promoters), independent of classical antigen-specific adaptive memory.
Combined with genuine antigen-specific memory T cells generated against shared tumor antigens, this dual memory system explains why: • Recurrence-free intervals after successful BCG extend well beyond the treatment period itself • Maintenance instillations (re-exposure) are needed periodically to sustain protection, rather than a single course providing lifelong immunity • BCG is fundamentally an active immunotherapy, not a cytotoxic drug — its benefit depends on a competent host immune system, explaining reduced efficacy in immunosuppressed patients
The clinical power of BCG lies in its schedule: a structured 6-week induction course followed by periodic maintenance instillations for up to three years, as defined by the landmark SWOG (Southwest Oncology Group) trial. This protocol delivers the largest reduction in recurrence of any intravesical agent for high-risk NMIBC — at the cost of substantial, mostly manageable, local and occasionally systemic toxicity.
The regimen validated by SWOG 8507 (Lamm et al., 2000) and adopted worldwide:
• Induction: one instillation weekly for 6 consecutive weeks, beginning 2–4 weeks after TURBT • Maintenance: a 3-week course (3 weekly instillations) repeated at 3, 6, 12, 18, 24, 30, and 36 months after induction — for high-risk patients able to tolerate it • Cystoscopic surveillance with urine cytology is performed at each maintenance interval to detect recurrence early • Full 3-year maintenance is associated with significantly better recurrence-free and progression-free survival than induction alone — the SWOG trial showed a doubling of median recurrence-free survival (36 vs. 20 months) with maintenance
Adherence is a major real-world challenge: toxicity, BCG shortages, and the multi-year time commitment mean a substantial fraction of patients do not complete the full maintenance schedule.
Compared with TURBT alone or intravesical chemotherapy, BCG (with maintenance) is the most effective agent for reducing recurrence in high-risk NMIBC:
• Recurrence reduction: approximately 30–40% relative reduction versus TURBT alone; superior to mitomycin C for high-grade tumors and CIS • Progression to muscle-invasive disease: maintenance BCG reduces progression risk, particularly important in T1 high-grade and CIS, though a meaningful fraction still progress • CIS complete response: roughly 70% achieve complete response after induction, though many eventually recur, requiring maintenance or re-induction • BCG-unresponsive disease: defined by AUA/FDA criteria as persistent/recurrent high-grade disease within 12 months of adequate BCG (≥5 of 6 induction + ≥2 of 3 maintenance, or two induction courses) — affects roughly 20–30% of high-risk patients by 2 years and is an indication for radical cystectomy or a clinical trial of novel agents (e.g., nadofaragene firadenovec, pembrolizumab, nogapendekin alfa)
BCG-unresponsive disease is now a formally defined regulatory category (FDA 2018 guidance) specifically to enable clinical trials of new bladder-sparing therapies for the substantial minority of patients whose tumors fail to respond adequately to BCG.
Because BCG works by deliberately provoking inflammation, side effects are common and expected — but must be distinguished from rare, dangerous systemic complications:
• Local irritative symptoms (~90% of patients, mostly mild-to-moderate): dysuria, urinary frequency/urgency, and low-grade fever for 24–48 hours after instillation — a granulomatous cystitis reflecting the intended immune response • Hematuria: common, usually self-limited • Systemic flu-like symptoms (malaise, low fever, arthralgia): fairly common, generally resolve within 48 hours • Granulomatous prostatitis, epididymo-orchitis: uncommon local complications • Severe local toxicity or persistent high fever (>39.5°C for >12h): may require withholding subsequent doses, dose reduction, or empiric anti-tuberculous therapy (isoniazid ± others) • Systemic BCGosis/BCG sepsis: rare (<1% of patients) but potentially life-threatening disseminated infection, typically from bacillemia after traumatic catheterization or instillation into an actively bleeding/inflamed bladder — presents with high fever, hypotension, multi-organ involvement, and requires urgent multidrug anti-tuberculous therapy plus corticosteroids
Given this toxicity profile, careful patient selection, technique, and monitoring throughout the multi-year maintenance schedule are essential to delivering BCG's substantial oncologic benefit safely.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Low risk | Primary, solitary Ta LG, <3cm | Single immediate post-TURBT chemo instillation only | Avoids unnecessary BCG toxicity/shortage use |
| Intermediate risk | Recurrent/multifocal Ta LG | Intravesical chemo course or 1-year BCG | Balances efficacy with BCG supply conservation |
| High risk | Any T1, high-grade Ta, or CIS | 6-week induction + SWOG maintenance to 3 years | ~30–40% recurrence reduction, delays progression |
| BCG-unresponsive | Persistent/recurrent HG disease within 12mo of adequate BCG | Radical cystectomy or novel bladder-sparing agent/trial | Prevents progression to incurable muscle-invasive cancer |